Lancet study makes BIG breakthrough, says 1 in 8 SARS-CoV-2 patients develop long COVID symptoms

London: One in eight adults who are infected with the SARS-CoV-2 virus experience long term symptoms due to COVID-19, according to a large Dutch study published on Friday in The Lancet journal. The study provides one of the first comparisons of long-term symptoms after SARS-CoV-2 infection, called 'long COVID', with symptoms in an uninfected population, as well as those in individuals both pre- and post-COVID-19 infection.

The inclusion of uninfected populations enables a more accurate prediction of long-term COVID-19 symptom prevalence as well as improved identification of the core symptoms of long COVID.

"There is urgent need for data informing the scale and scope of the long-term symptoms experienced by some patients after COVID-19 illness,” said Professor Judith Rosmalen from the University of Groningen in The Netherlands.

“However, most previous research into long COVID has not looked at the frequency of these symptoms in people who haven't been diagnosed with COVID-19 or looked at individual patients' symptoms before the diagnosis of COVID-19,” said Rosmalen, lead author of the study.

The study looked at the symptoms most often associated with long COVID, including breathing problems, fatigue and loss of taste and smell, both before a COVID-19 diagnosis and in people who have not been diagnosed with the disease.

The researchers collected data by asking participants to regularly fill out digital questionnaires on 23 symptoms commonly associated with long COVID.

The questionnaire was sent out 24 times to the same individuals between March 2020 and August 2021, meaning participants who had COVID-19 during this time were infected with the SARS-CoV-2 Alpha-variant or earlier variants.

Most of the data was collected before the COVID-19 vaccine rollout in The Netherlands so the number of vaccinated participants was too small to analyse.

Of 76,422 participants, 4,231 participants who had COVID-19 were matched to 8,462 controls taking account of sex, age and time of completing questionnaires that indicated a COVID-19 diagnosis.

The researchers found that several symptoms were new or more severe three to five months after having COVID-19, compared to symptoms before a diagnosis and to the control group, suggesting these symptoms can be viewed as the core symptoms of long COVID.

The core symptoms recorded were chest pain, difficulties breathing, pain when breathing, painful muscles, loss of taste or smell, tingling hands and feet, a lump in throat, alternately feeling hot and cold, heavy arms or legs and general tiredness.

The severity of these symptoms plateaued at three months after infection with no further decline, according to the researchers.

Other symptoms that did not significantly increase three to five months after a COVID-19 diagnosis included headache, itchy eyes, dizziness, back pain and nausea, they said.

"These core symptoms have major implications for future research, as these symptoms can be used to distinguish between post COVID-19 condition and non-COVID-19-related symptoms," said PhD candidate Aranka Ballering, first author of the study.

Of the study participants who had submitted pre-COVID symptom data, the researchers found that 21.4 per cent of COVID-19-positive participants, compared to 8.7 per cent of the control group, experienced at least one increased core symptom at moderate severity 3 months or more after SARS-CoV-2 infection.

This implies that in 12.7 per cent of COVID-19 patients their new or severely increased symptoms three months post-COVID can be attributed to SARS-CoV-2 infection.

"By looking at symptoms in an uninfected control group and in individuals both before and after SARS-CoV-2 infection, we were able to account for symptoms which may have been a result of non-infectious disease health aspects of the pandemic, such as stress caused by restrictions and uncertainty," Ballering added.

"Post-COVID-19 condition, otherwise known as long COVID, is an urgent problem with a mounting human toll.

"Understanding the core symptoms and the prevalence of post-COVID-19 in the general population represents a major step forward for our ability to design studies that can ultimately inform successful healthcare responses to the long-term symptoms of COVID-19," he added.

The authors acknowledge some limitations in the study as it included patients infected with the Alpha variant or earlier variants of SARS-CoV-2 and has no data from people infected during the period when the Delta or Omicron variants were causing most infections.

Also, due to asymptomatic infection, the prevalence of COVID-19 in this study may be underestimated, the researchers said.

Another limitation to the study is that since the beginning of data collection other symptoms, such as brain-fog, have been identified as potentially relevant for a definition of long COVID but this study did not look at these symptoms, they added.